Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • Switzerland leads the way in spin-offs

    Swiss universities and the Swiss innovation system as a whole consistently perform very well in rankings, while the start-up ecosystem usually revealed some weaknesses. The…

    startupticker.ch

    • Switzerland ranks third in VC-backed deep tech and life sciences spinouts behind UK and France, leading per capita.
    • ETH Zurich and EPFL produced 63 robotics spinoffs combined—more than eight other top European universities together.
    • European spinouts worth $398 billion created 167,000 jobs, but nearly 50% of late-stage funding comes from the US.
    startupticker.ch: Switzerland leads the way in spin-offs

  • A $16M round and key milestones strengthen Sunflower Labs’s position

    Sunflower Labs, creator of the Beehive autonomous security drone system has obtained nationwide FAA approval to operate beyond visual line of sight (BVLOS) across the…

    startupticker.ch

    • Sunflower Labs won FAA nationwide approval for autonomous BVLOS drone flights over people and vehicles without case-by-case approval.
    • Sunflower Labs closed $16M Series B funding led by Sequoia Capital to expand AI development and operations globally.
    • Sunflower Labs launched an online tool for customers to preview Beehive system coverage on their property before purchase.
    startupticker.ch: A $16M round and key milestones strengthen Sunflower Labs’s position

  • $150 million to scale DEXTER the surgical robot across the US

    Distalmotion, the developer of surgical robot DEXTER which is designed to empower access to the benefits of robotic surgery in outpatient sites of care, has…

    startupticker.ch

    • Distalmotion raised $150M Series G funding led by Revival Healthcare Capital to accelerate US adoption of its DEXTER surgical robot.
    • DEXTER has treated nearly 3,000 patients in Europe and US with a compact design requiring no operating room modifications.
    • Chas McKhann, ex-CEO of two public medical device companies, joined as Executive Chairman to lead ASC market expansion.
    startupticker.ch: $150 million to scale DEXTER the surgical robot across the US

  • Albatross raises CHF 9.7 million to reinvent product discovery for the web

    Former Amazon AI leaders raise CHF 9.7 m to deploy AI that understands user intent in real time, transforming how they discover products and content…

    startupticker.ch

    • Albatross raised €10.5M for real-time AI that adapts to user intent, replacing static recommendation systems.
    • Founded by ex-Amazon AI leaders, Albatross serves billions of live events monthly with integration in under seven weeks.
    • Early pilots showed triple-digit engagement gains, positioning real-time personalization as the next AI evolution step.
    startupticker.ch: Albatross raises CHF 9.7 million to reinvent product discovery for the web

  • Indivi secures CHF 15 million

    TechBio company Indivi has closed a CHF15 million investment round led by Ava Investors to accelerate the validation and deployment of precision medicine tools in…

    startupticker.ch

    • Indivi raised CHF15 million from Ava Investors to develop digital biomarkers for accelerating Alzheimer's drug development.
    • The company's smartphone tools capture motor, cognitive, vision, and voice data for regulatory trials and clinical use.
    • Indivi plans a 2026 trial to identify biomarkers for amyloid-depleting Alzheimer's therapies.
    startupticker.ch: Indivi secures CHF 15 million

  • CHF 172 million for growth start-ups

    Following the first closing of the Swisscanto (CH) Private Equity Switzerland Growth II fund, managed by Zürcher Kantonalbank, investment activities will now commence. The majority…

    startupticker.ch

    • Swisscanto Private Equity Switzerland Growth II raised CHF 171.65 million from 45 investors in eight months.
    • The fund invests in Swiss growth companies with innovative tech in health, industry, and data services.
    • Zürcher Kantonalbank's PE programs manage nearly CHF 500 million across three funds, including a decarbonisation fund.
    startupticker.ch: CHF 172 million for growth start-ups

  • NNAISENSE gets acquired by Germany asset management firm

    Based in Lugano, NNAISENSE has built a generative AI framework for financial markets to enable the prediction of coherent market scenarios across multiple asset classes,…

    startupticker.ch

    • ACATIS Investment KVG acquired NNAISENSE to gain exclusive access to its Large Investing Model for predicting financial market scenarios.
    • NNAISENSE's LIM, developed by DeepMind's Alex Graves, analyzes multiple asset classes and macroeconomic, fundamental, and alternative data.
    • NNAISENSE maintains its Lugano headquarters and will focus exclusively on developing the LIM for ACATIS's portfolio management.
    startupticker.ch: NNAISENSE gets acquired by Germany asset management firm

  • Delvitech closes USD 40 million Series B round to accelerate global growth

    Delvitech, specializing in the development of AI-native Automated Optical Inspection (AOI) solutions for electronics, closed a Series B investment round of USD 40 million. Delvitech…

    startupticker.ch

    • Delvitech raised $40M in Series B funding to expand its AI-native optical inspection platform globally, with an Indian plant planned for 2026.
    • Delvitech's neural networks and Swiss hardware enable predictive quality control that anticipates errors rather than detecting them in PCB components.
    • Delvitech projects 400% sales growth by end of 2025 and added neural networks pioneer Prof.
    startupticker.ch: Delvitech closes USD 40 million Series B round to accelerate global growth

  • Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study

    BioVersys’ lead asset BV100, an innovative anti-infective developed for hospital infections caused by Acinetobacter baumannii, including carbapenem resistant strains (CRAB), has been selected to participate…

    startupticker.ch

    • BioVersys' BV100, a novel IV rifabutin formulation, selected for ADVANCE-ID Phase 2b trial targeting carbapenem-resistant Acinetobacter baumannii.
    • Wellcome funding of SGD 22 million enables first sponsor-driven ADVANCE-ID trial, expanding enrollment to 90 and adding combination therapy arms.
    • First patient dosing expected H1 2026 with interim data H2 2026, supporting BV100's Phase 3 program for US, European, and Chinese submissions.
    startupticker.ch: Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study

  • AstraZeneca acquires SixPeaks for up to USD 300 million

    Following an initial investment of USD 15 million in 2024, AstraZeneca has acquired Basel-based SixPeaks Bio AG. SixPeaks is investigating potential therapies for weight-management with…

    startupticker.ch

    • AstraZeneca acquired Basel-based SixPeaks Bio for up to $300M, exercising an option after a $15M 2024 investment.
    • SixPeaks develops activin IIA/B receptor antibodies to preserve muscle mass, addressing a GLP-1 drug limitation.
    • SixPeaks created a first-in-class GLP-1 antibody conjugate combining weight loss with muscle preservation.
    startupticker.ch: AstraZeneca acquires SixPeaks for up to USD 300 million

  • Positrigo on a growth momentum in the US

    One year following the acquisition of its first customer in the US market, Positrigo continues to strengthen its position in America. The company has installed…

    startupticker.ch

    • Positrigo's FDA-cleared NeuroLF brain PET scanner is rapidly expanding in the US market with multiple installations.
    • New Alzheimer's disease-modifying therapies are driving demand for brain PET scans, creating market opportunities.
    • Positrigo expanded operations with new executives and board members, strengthening European distribution in Spain and France.
    startupticker.ch: Positrigo on a growth momentum in the US

  • CDR-Life to receive up to CHF 456 million in license agreement with Boehringer Ingelheim

    Building on their longstanding partnership in retinal health, Boehringer Ingelheim and CDR-Life, Inc. have entered a new global licensing agreement to develop CDR-Life’s antibody-based molecule…

    startupticker.ch

    • Boehringer Ingelheim licensed CDR111, a trispecific antibody T-cell engager, with up to CHF 456M in milestone and royalty payments.
    • CDR111 selectively depletes dysregulated B cells to reset immunity, potentially treating lupus, MS, and arthritis.
    • The partnership expands prior collaboration on a Phase 2 geographic atrophy treatment, validating CDR-Life's platform.
    startupticker.ch: CDR-Life to receive up to CHF 456 million in license agreement with Boehringer Ingelheim